Skip to main content
. 2021 Oct 29;8:750381. doi: 10.3389/fcvm.2021.750381

Figure 3.

Figure 3

Cost-effectiveness acceptability curve. Iterations of the cost-effectiveness of empagliflozin vs. placebo under different willingness to pay thresholds in Taiwan, Japan, South Korea, Singapore, Thailand, and Australia.